These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28699529)

  • 21. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
    Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods of resistance to epidermal growth factor receptor inhibition in glioblastoma multiforme.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2012 Feb; 70(2):N13-4. PubMed ID: 22251981
    [No Abstract]   [Full Text] [Related]  

  • 30. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
    Frumento D; Grossi G; Falesiedi M; Musumeci F; Carbone A; Schenone S
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
    Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
    Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.
    Tsigelny IF; Mukthavaram R; Kouznetsova VL; Chao Y; Babic I; Nurmemmedov E; Pastorino S; Jiang P; Calligaris D; Agar N; Scadeng M; Pingle SC; Wrasidlo W; Makale MT; Kesari S
    Oncotarget; 2017 Apr; 8(14):22370-22384. PubMed ID: 26517684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TSPO as a target for glioblastoma therapeutics.
    Werry EL; Barron ML; Kassiou M
    Biochem Soc Trans; 2015 Aug; 43(4):531-6. PubMed ID: 26551689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent medical management of glioblastoma.
    Johnson DR; Chang SM
    Adv Exp Med Biol; 2012; 746():26-40. PubMed ID: 22639157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of octamer binding transcription factors in glioblastoma multiforme.
    Rooj AK; Bronisz A; Godlewski J
    Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.